Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Thursday 26 February 2026 10:03 pm  |  Updated:  Friday 27 February 2026 10:35 am

Sun Nuclear QADS 2026 Event Combines Clinical Insight and New Innovations for Advancing Radiation Therapy QA

By: Business Wire

Add as a preferred source on Google

Sun Nuclear, a Mirion Medical company, today opened the QA & Dosimetry Symposium (QADS), taking place over the next two days in Rome, Italy. The 15th installment brings together more than 230 clinical physicists and radiation medicine professionals from nearly 40 countries. Participants from diverse clinical environments will earn continuing education credits while sharing practical insights, emerging approaches, and real-world experiences shaping the future of quality and patient safety in cancer care.

Building on its legacy as a peer-driven forum with practical applications, QADS 2026 features sessions delivered by 24 speakers spanning:

  • Future Directions in Machine and Patient QA and In-vivo Dosimetry
  • Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) QA
  • Safety and Guideline-driven Tool Selection
  • Emerging Technologies, including Theranostics, AI and Automation

Reinforcing its role as a launch point for clinically grounded innovation, QADS 2026 will serve as the introduction of Daily QA™ 4 Pro, Sun Nuclear’s latest advancement for daily machine QA. Attendees will receive an early look at how Daily QA 4 Pro combines dosimetry and imaging/positioning checks into one indexed, imageable device that supports faster setup, fewer room entries and more consistent workflows.

David Barbee, Ph.D., DABR, of NYU Langone Health will deliver a keynote presentation exploring early clinical experience with the Daily QA 4 Pro device. The session examines the evolving landscape of daily machine quality assurance, drawing on comparative measurement data from independent QA tools and machine performance checks to highlight how diverse data sources can be reviewed, interpreted and meaningfully integrated into clinical QA workflows. Through real‑world examples, the discussion will address efficiencies, limitations of existing approaches, and emerging opportunities to improve data visibility, trend analysis and workflow understanding—setting the stage for informed dialogue on the future direction of machine QA.

In addition, QADS will feature demonstrations of an AI-powered plan quality enablement solution, Plan AI™, which recently received CE mark, making it available for sale in Europe. Attendees can explore how Plan AI simultaneously accelerates radiation planning speeds and elevates plan quality and consistency. These demonstrations complement the symposium’s technical sessions by offering hands-on exposure to emerging capabilities.

“As clinical quality management demands continue to grow, forums like QADS play a critical role in bringing the community together to share experiences, evaluate new approaches, and focus on what delivers real value in practice,” said Luis Rivera, Executive Vice President for Mirion Medical, and President for Sun Nuclear. “QADS reflects our commitment to supporting physicists and clinical care teams with solutions and conversations that are grounded in clinical reality and focused on improving quality and efficiency.”

To learn more about QADS, visit qasymposium.com.

About Mirion

Mirion is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Technologies group is committed to powering advancements in nuclear energy through proven radiation safety technologies and expertise. The Mirion Medical group is focused on improving quality in cancer care through its broad range of solutions that enhance delivery and ensure safety across the medical landscape. Headquartered in Atlanta (GA – USA), Mirion employs approximately 3,200 people and operates in 12 countries.

Varian Medical Systems® is a registered trademark, and Varian™ and Machine Performance Checks are trademarks, of Varian Medical Systems, Inc. Sun Nuclear is not affiliated with or sponsored by Varian Medical Systems, Inc.

©2026 Mirion. All rights reserved. Plan AI and Daily QA 4 Pro are trademarks or registered trademarks of Mirion Technologies, Inc. and/or its affiliates in the United States and/or other countries.

Radiation therapy experts discuss innovations at Sun Nuclear QADS 2026 in Rome, featuring new Daily QA™ 4 Pro device.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260226537656/en/

Contact

For media inquiries:
Erin Schesny
[email protected]

For investor inquiries:
Eric Linn
[email protected]

Company Logo
Company Logo
Read more

Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Businesswire

Categories

  • Event
  • Trade Show

Trending Articles

  • Billionaire Easyjet founder in line for £800m payday from takeover

  • Pension pressure to help swell UK debt to three times size of economy

  • As it happened: FTSE 100 slump as oil soars; Trump says Iran will be ‘hit hard’ tonight

  • Construction sector cuts jobs again as house building slumps

  • Burnham told to launch £100bn tax reform package

More from City PM

  • Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform

    Business Wire
  • cTAP Announces Novel Prognostic Score Developed for Duchenne Muscular Dystrophy Patients Offers Improved Prediction of Loss of Ambulation

    Business Wire
  • Overture Life Launches Global ICSI.A Center of Excellence Program, Bringing the World’s First Automated ICSI into Clinical Use Across Five Leading Global Fertility Centers

    Business Wire
  • Mosaic Clinical Technologies™ Launches Mosaic Reporting™, an AI-Native Reporting Platform Built for Radiology Workflows

    Business Wire
  • ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development

    Business Wire
  • IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease

    Business Wire
  • Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

    Business Wire
  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy